Form 4: 89bio Director Acquires Stock Options
SEC Form 4 Filing
Director Edward Morrow Atkinson III acquires stock options for 56,400 shares of 89bio, Inc.
Summary
- Edward Morrow Atkinson III, a director of 89bio, Inc., was granted stock options on February 3, 2025.
- The options allow him to purchase 56,400 shares of 89bio's common stock at an exercise price of $9.60 per share.
- The options will vest in full on February 1, 2026, contingent upon Atkinson's continued service to the company.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- The vesting schedule of the options, with full vesting after approximately one year of continued service, is typical for such grants.
- The number of shares granted is dependent on the size of the company and the role of the director.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of the transaction (grant of stock options). |
| 02/01/2026 | Date the stock options vest in full. |
| 02/03/2035 | Expiration date of the stock options. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.